Qiagen N.v. · NYSE:QGEN
Qiagen — J.P. Morgan Healthcare Conference 2021
15 slides from Qiagen's conference presentation, Jan 12, 2021
Slide 1: A stronger focused company set for solid post-pandemic growth
A stronger focused company set for solid post-pandemic growth Thierry Bernard Chief Executive Officer J.P. Morgan Healthcare Conference January 12, 2021 Sample to Insight
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking governments, global or regional economic developments, weather or transportation delays, statements. All statements other than statements of historical fact are, or may b
Slide 3: QIAGEN at a glance
QIAGEN at a glance 9M 2020 sales Global sales $1.3 bn 45% Americas 48% 52% 35% EMEA 20% Asia-Pacific / Japan Molecular Life Diagnostics Sciences >5,300 86% 14% employees Consumables Instruments Innovative cutting-edge portfolios worldwide and related revenues • Trusted brand known for quality and ex
Slide 4: 2020: Key achievements amid a year of unprecedented change
2020: Key achievements amid a year of unprecedented change Launched >10 new solutions to expand COVID-19 Significantly scaled-up global manufacturing capacity portfolio to address phases of the pandemic for products used in COVID-19 testing RNA sample technologies • QIAprep& Received the first FD
Slide 5: Strong performance exceeding outlook increases throughout the year
Strong performance exceeding outlook increases throughout the year 2020 Net sales 2020 Adjusted diluted EPS (in $ millions, at actual rates) (in $ per share, at actual rates) ~$0.64-0.65 ≥+32% CER +61% CER CER +70% CER +26% CER $0.58 +19% CER $0.55 $483.8 $443.3 +9% CER $372.1 +26% CER $0.34 Q1 Q2 Q
Slide 6: Set to deliver high-demand COVID-19 testing and post-pandemic market solutions
Set to deliver high-demand COVID-19 testing and post-pandemic market solutions Meaningful COVID-19 impact in 2020 Moving into 2021 with an accelerated installed base 2020 9M net sales +18% CER $1,299 m $1,113 m COVID-related +313% CER Non-COVID -12% CER 2019 2020 Accelerated instrument “Test and Tre
Slide 7: Solutions for COVID-19 testing and treatment decisions to support pandemic control
Solutions for COVID-19 testing and treatment decisions to support pandemic control Effects of vaccination not expected before H2 2021 November 2020 estimate Probability of functional end September 2020 estimate January 2021 estimate Immunity testing: Antibody and T cell tests PCR and antigen testing
Slide 8: 2020 and beyond: Unwavering focus on five pillars of growth
2020 and beyond: Unwavering focus on to five pillars of growth 2019: 2020 and beyond: Pursuing a broad range of opportunities Sharpened focus on five pillars of growth Portfolio with multiple new launches – but diluted efforts Ability to take top 3 leadership position with waves of organic growth Sa
Slide 9: Five pillars targeting >$6 billion opportunities of our $11 billion total addressable market
Five pillars targeting >$6 billion opportunities of our $11 billion total addressable market Sample technologies QIAcuity QIAstat-Dx NeuMoDx QuantiFERON Strengthen excellence in Enter digital PCR market Accelerate Fully integrate Extend leadership in Sample technologies with QIAcuity QIAstat-Dx adop
Slide 10: Reinvesting COVID-19 tailwinds to drive further waves of growth in 5 pillars
Reinvesting COVID-19 tailwinds to drive further waves of growth in 5 pillars Executing on a roadmap to fuel robust growth beyond 2021 Current status 2021 2022 2023 and beyond Sample Broadest portfolio with • New automation workflows • New applications • Next generation platforms technologies leading
Slide 11: 2021 and beyond: Continuing to capture opportunities in dynamic markets
2021 and beyond: Continuing to capture opportunities in dynamic markets 2020 2021 Post-COVID dynamics Sample >$750 million ~$770-780 million • Sustainable low- to mid-single-digit CER growth technologies (Includes ~$60 m decrease in manual RNA sample prep sales) QIAcuity ~$10 million >$45 million •
Slide 12: Fostering a culture of empowerment driven by a focus on achieving targets
Fostering a culture of empowerment driven by a focus on achieving targets Decentralizing decision-making Setting ambitious but realistic targets Creating a culture of “doers” • Giving teams at all levels greater influence • Appropriately balance opportunity and risk • Foster a stronger culture of ow
Slide 13: Disciplined capital allocation strategy to support business growth while increasing returns
Disciplined capital allocation strategy to support business growth while increasing returns Business reinvestment Leverage ratio(1) Fuel sustainable and profitable growth, 1.8 especially in five pillars 1.6 1.6 1.5 1.4 1.3 1.2 1.1 Disciplined Share repurchase programs 0.9 capital Commitment to incre
Slide 14: Outlook for solid growth in 2020 and beyond
Outlook for solid growth in 2020 and beyond(1) Net sales Adjusted EPS Q4 2020 >+32% CER growth ~$0.64-0.65 CER FY 2020 ~+22% CER growth ~$2.13-2.14 CER(2) FY 2021 ~+18-20% CER(3) ~$2.42-2.46 CER(3) Improving trends in non-COVID products while Balancing efficiency gains with R&D supporting pandemic t
Slide 15: Summary
Summary COVID-19 accelerating the execution of our long-term growth strategy 1 Rapid growth in installed base and sales momentum – now investing to strengthen test menus Strong business with unwavering focus on five pillars of growth 2 Sharpening our focus and investments to drive market share gains